title: Age differences in the adherence to treatment guidelines and outcome in patients with ST-elevation myocardial infarction.
abstract: The aim of this study was to assess age differences in the utilization of class-I treatment guidelines and its effect on mortality in patients with ST-elevation myocardial infarction (STEMI). The study included 1026 consecutive patients from the prospective nationwide Acute Coronary Syndrome Israeli Survey (ACSIS). Primary reperfusion was used less often among elderly (age>75 years) patients than among those aged 65-74 and <65 years (46%, 63%, 64%, respectively, p (for trend)=0.004). Class-I evidence-based medications (EBM) at discharge (aspirin, β-blockers, angiotensin converting-enzyme inhibitors=ACEI, angiotensin receptor-blockers=ARBs and statins) were less frequently prescribed to elderly compared to younger age-subgroup (44%, 61%, 57%, respectively; adjusted odds ratio (OR)=0.62; 0.40-0.97 for age ≥ 75 vs. age<65 years). Early and 1-year mortality rates were 3-5-fold higher among the elderly compared to patients <65 years. In the entire cohort use of primary reperfusion was associated with lower 1-year mortality (OR=0.69; 0.47-1.01), as was the use of EBM (OR=0.26; 0.17-0.41). These effects were similar across all age-subgroups but with a greater impact among the elderly, as the number of patients needed to treat (NNT) was significantly lower with advancing age. Better adherence to treatment guidelines may improve the prognosis of elderly patients with STEMI.
authors.affiliation: Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer 52621, Israel. shmuelg@ekmd.huji.ac.il
authors.forename: Shmuel
authors.initials: S
authors.lastname: Gottlieb
authors.forename: Solomon
authors.initials: S
authors.lastname: Behar
authors.forename: Roseline
authors.initials: R
authors.lastname: Schwartz
authors.forename: David
authors.initials: D
authors.lastname: Harpaz
authors.forename: Avraham
authors.initials: A
authors.lastname: Shotan
authors.forename: Doron
authors.initials: D
authors.lastname: Zahger
authors.forename: Hanoch
authors.initials: H
authors.lastname: Hod
authors.forename: Dan
authors.initials: D
authors.lastname: Tzivoni
authors.forename: Mady
authors.initials: M
authors.lastname: Moriel
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000367:Age Factors; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D016009:Chi-Square Distribution; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007557:Israel; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D015425:Myocardial Reperfusion / Q000706:statistics & numerical data; D016017:Odds Ratio; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D001241:Aspirin